| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tetramethylammonium hydrogensulfate does not have a defined pharmacological target as it is a quaternary ammonium salt and chemical reagent. The compound is extensively used as a catalyst and phase transfer agent in chemical reactions, especially in organic synthesis. In addition, it is used as an electrolyte additive in electrochemical and rechargeable batteries.
|
|---|---|
| ln Vitro |
In research pertaining to life sciences, tetramethylammonium hydrogensulfate is a biochemical reagent that can be utilized as an organic compound or biological material.
No specific in vitro pharmacological activity data are available for Tetramethylammonium hydrogensulfate as a drug candidate. In research settings, the compound is used as a catalyst, phase transfer agent, and electrolyte additive. Its activity is assessed in terms of catalytic efficiency and electrochemical properties rather than biological activity. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Tetramethylammonium hydrogensulfate as a therapeutic agent. The compound is used as a chemical reagent and catalyst. It is not administered to animals for pharmacological evaluation. Its applications are limited to organic synthesis and electrochemical research.
|
| Enzyme Assay |
For non-cellular assays, Tetramethylammonium hydrogensulfate is characterized by standard analytical techniques including NMR, HPLC, and elemental analysis to confirm identity and purity. The compound can be evaluated as a catalyst in organic reactions and as an electrolyte in electrochemical studies. Purity: 99+%, HPLC grade. Molecular weight: 171.21 g/mol.
|
| Cell Assay |
For in vitro cell-based studies, Tetramethylammonium hydrogensulfate is not typically used as a direct test compound. The compound is intended for synthetic chemistry and electrochemical applications. If handled in a biological laboratory context, appropriate safety precautions should be taken due to the quaternary ammonium structure.
|
| Animal Protocol |
For in vivo animal studies, Tetramethylammonium hydrogensulfate is not typically administered as a test compound. The compound is used as a chemical reagent. If used in toxicological studies, it would be administered via appropriate routes with suitable formulations.
|
| ADME/Pharmacokinetics |
Tetramethylammonium hydrogensulfate has a molecular weight of 171.22 and molecular formula C4H13NO4S. Purity: 99+%, HPLC grade. Storage: keep in a cool, dry place protected from light and moisture. The compound is a solid at room temperature.
|
| Toxicity/Toxicokinetics |
Tetramethylammonium hydrogensulfate is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Quaternary ammonium compounds and acid salts should be handled with care. Appropriate personal protective equipment including gloves and safety glasses should be worn.
|
| Additional Infomation |
Tetramethylammonium hydrogensulfate (CAS 80526-82-5) is also known as TMAHS, tetramethylammonium bisulfate, and tetramethylazanium hydrogen sulfate. It is used as a catalyst, phase transfer agent, and electrolyte additive. Applications include organic synthesis and electrochemical research. No clinical trials or therapeutic approvals exist.
|
| Molecular Formula |
C4H13NO4S
|
|---|---|
| Molecular Weight |
171.22
|
| Exact Mass |
171.057
|
| CAS # |
80526-82-5
|
| Related CAS # |
Tetramethylammonium acetate hydrate;1266615-86-4
|
| PubChem CID |
157340
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
290ºC
|
| LogP |
0.407
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
95.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[N+](C)(C)C.OS(=O)(=O)[O-]
|
| InChi Key |
DWTYPCUOWWOADE-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C4H12N.H2O4S/c2*1-5(2,3)4/h1-4H3;(H2,1,2,3,4)/q+1;/p-1
|
| Chemical Name |
hydrogen sulfate;tetramethylazanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8404 mL | 29.2022 mL | 58.4044 mL | |
| 5 mM | 1.1681 mL | 5.8404 mL | 11.6809 mL | |
| 10 mM | 0.5840 mL | 2.9202 mL | 5.8404 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
